A compound of following general formula: or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture, wherein: - Y 1 and Y 4 each represent, independently of each other, a CH group or a nitrogen atom on the condition that at least one of Y 1 and Y 4 represent a nitrogen atom, - Y 2 represents a C-X-Ar group, - Y 3 represents a C-W group, - Ar represents an aryl or heteroaryl group optionally substituted by one or more groups selected from a halogen atom, (C 1 -C 6)alkyl, (C 1 -C 6)haloalkyl, (C 1 -C 6)haloalkoxy, (C 1 -C 6)halothioalkoxy, CN, NO 2, OR 11, SR 12, NR 13 R 14, CO 2 R 15, CONR 16 R 17, SO 2 R 18, SO 2 NR 19 R 20, COR 21, NR 22 COR 23, NR 24 SO 2 R 25, and R 26 NR 27 R 28 and/or optionally fused to a heterocycle, - X represents a divalent group selected from O, S, S, S 2, NR 4, S(NR 4), S (NR 4), S 2 (NR 4), NR 4 S, NR 4 S, NR 4 S 2, CH 2, CH 2 S, CH 2 S, CH 2 S 2, SCH 2, S CH 2, S 2 CH 2, CH 2 CH 2, CH=CH, C≡C, CH 2 O, OCH 2, NR 4 CH 2, and CH 2 NR 4, - W represents an R 5, SR 5, OR 5 or NR 5 R 6 group, - U represents a CH 2 or NH group, one or more hydrogen atoms which may be replaced by a (C 1 -C 6)alkyl group, - V represents C, C or CH 2, - n represents 0 or 1, - R 1 represents a hydrogen atom, or an OR 7 or NR 7 R 8 group, - R 2 represents a hydrogen atom, an optionally substituted heterocycle, NO 2, OR 9 or NR 9 R 10, - R 3, R 4, R 11 to R 25 and R 27 to R 28 each represent, independently of each other, a hydrogen atom or a (C 1 -C 6)alkyl group, - R 5 and R 6 each represent, independently of each other, a hydrogen atom or a (C 1 -C 6)alkyl, optionally substituted aryl or optionally substituted benzyl group, - R 7, R 8, R 9 and R 10 each represent, independently of each other, a hydrogen atom or an optionally substituted (C 1 -C 6)alkyl or (C 3 -C 12)cycloalkyl group or an optionally substituted heterocycle, and - R 26 represents a (C 1 -C 6)alkyl group, for use in the treatment of a cancer associated with the overexpression of at least one Trk protein. - Y 1 and Y 4 each represent, independently of each other, a CH group or a nitrogen atom on the condition that at least one of Y 1 and Y 4 represent a nitrogen atom, - Y 2 represents a C-X-Ar group, - Y 3 represents a C-W group, - Ar represents an aryl or heteroaryl group optionally substituted by one or more groups selected from a halogen atom, (C 1 -C 6)alkyl, (C 1 -C 6)haloalkyl, (C 1 -C 6)haloalkoxy, (C 1 -C 6)halothioalkoxy, CN, NO 2, OR 11, SR 12, NR 13 R 14, CO 2 R 15, CONR 16 R 17, SO 2 R 18, SO 2 NR 19 R 20, COR 21, NR 22 COR 23, NR 24 SO 2 R 25, and R 26 NR 27 R 28 and/or optionally fused to a heterocycle, - X represents a divalent group selected from O, S, S, S 2, NR 4, S(NR 4), S (NR 4), S 2 (NR 4), NR 4 S, NR 4 S, NR 4 S 2, CH 2, CH 2 S, CH 2 S, CH 2 S 2, SCH 2, S CH 2, S 2 CH 2, CH 2 CH 2, CH=CH, C≡C, CH 2 O, OCH 2, NR 4 CH 2, and CH 2 NR 4, - W represents an R 5, SR 5, OR 5 or NR 5 R 6 group, - U represents a CH 2 or NH group, one or more hydrogen atoms which may be replaced by a (C 1 -C 6)alkyl group, - V represents C, C or CH 2, - n represents 0 or 1, - R 1 represents a hydrogen atom, or an OR 7 or NR 7 R 8 group, - R 2 represents a hydrogen atom, an optionally substituted heterocycle, NO 2, OR 9 or NR 9 R 10, - R 3, R 4, R 11 to R 25 and R 27 to R 28 each represent, independently of each other, a hydrogen atom or a (C 1 -C 6)alkyl group, - R 5 and R 6 each represent, independently of each other, a hydrogen atom or a (C 1 -C 6)alkyl, optionally substituted aryl or optionally substituted benzyl group, - R 7, R 8, R 9 and R 10 each represent, independently of each other, a hydrogen atom or an optionally substituted (C 1 -C 6)alkyl or (C 3 -C 12)cycloalkyl group or an optionally substituted heterocycle, and - R 26 represents a (C 1 -C 6)alkyl group,